SCHEMBL17009233

SCHEMBL17009233

NC(=O)CCCCCCC(=O)NCc1cccs1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.85
POLB P06746 4/20 0.69
MAPT P10636 2/20 0.64
TSHR P16473 2/20 0.64
HPGD P15428 7/20 0.62
ALDH1A1 P00352 4/20 0.62
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
TP53 P04637 1/20 0.55
ALOX15 P16050 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55
KDM4E B2RXH2 1/20 0.53
GRK2 P25098 1/20 0.52
PTPN7 P35236 1/20 0.52
RECQL P46063 1/20 0.52
CTDSP1 Q9GZU7 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7694996 1.00 USP2 (0.85) USP2POLBMAPTTSHRHPGD
SCHEMBL17009271 0.98 USP2 (0.88) USP2POLBMAPTTSHRHPGD
SCHEMBL17009332 0.95 USP2 (0.82) USP2POLBMAPTTSHRHPGD
SCHEMBL13438260 0.89 USP2 (0.93) USP2POLBMAPTTSHRHPGD
SCHEMBL9784530 0.87 USP2 (0.82) USP2POLBMAPTTSHRHPGD
SCHEMBL8269685 0.85 USP2 (0.85) USP2POLBMAPTTSHRHPGD
SCHEMBL17205973 0.84 USP2 (0.84) USP2POLBMAPTTSHRHPGD
SCHEMBL28179817 0.84 USP2 (0.84) USP2POLBMAPTTSHRHPGD
SCHEMBL25283374 0.83 USP2 (0.82) USP2POLBMAPTTSHRHPGD
SCHEMBL1259782 0.82 POLB (1.00) USP2POLBMAPTTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311619-B2 Integrin activator vaccine compositions 7 Hills Pharma Inc. and Texas Heart Institute (US) 2022-04-26 US claimed
US-20210145796-A1 METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY 7 HILLS PHARMA INC. 2021-05-20 US claimed
US-20210023207-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS 7 Hills Pharma LLC (US) 2021-01-28 US claimed
US-10716849-B2 Methods of administering novel integrin activator vaccine compositions 7 Hills Pharma LLC (US) 2020-07-21 US claimed
US-10709780-B2 Integrin activator vaccine compositions 7 Hills Pharma LLC (US) 2020-07-14 US claimed
US-10709781-B2 Integrin activator checkpoint inhibitor compositions 7 Hills Pharma LLC (US) 2020-07-14 US claimed
US-20200054743-A1 NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS 7 Hills Pharma LLC (US) 2020-02-20 US claimed
US-20190351052-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS 7 Hills Pharma LLC (US) 2019-11-21 US claimed
US-20190343952-A1 METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS 7 Hills Pharma LLC (US) 2019-11-14 US claimed
US-20240189360-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS PHARMA INC. (US) 2024-06-13 US disclosed
CN-107820429-B Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants 7山药物有限责任公司 2022-08-16 CN disclosed
US-11311619-B2 Integrin activator vaccine compositions 7 Hills Pharma Inc. and Texas Heart Institute (US) 2022-04-26 US disclosed
EP-3104867-B1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 Hills Pharma LLC (US) 2022-01-19 EP disclosed
US-20210023207-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS 7 Hills Pharma LLC (US) 2021-01-28 US disclosed
US-20190343952-A1 METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS 7 Hills Pharma LLC (US) 2019-11-14 US disclosed
EP-3288585-A2 NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS 7 HILLS INTERESTS, LLC (US) 2018-03-07 EP disclosed
EP-3104867-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS INTERESTS, LLC (US) 2016-12-21 EP disclosed
US-20160339098-A1 Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants 7 HILLS PHARMA INC. 2016-11-24 US disclosed
WO-2016176400-A2 NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS 7 HILLS INTERESTS LLC (US) 2016-11-03 WO disclosed
WO-2015123447-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS PHARMA, LLC (US) 2015-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11311619-B2 Integrin activator vaccine compositions ITGAM, ITGA2B, ITGA1 USP2 3773/4885POLB 3433/4885MAPT 3555/4885
US-20200054743-A1 NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS CD47, ITGA1, ITGA2B USP2 3674/4885POLB 1392/4885MAPT 3558/4885
US-10709781-B2 Integrin activator checkpoint inhibitor compositions CD47, ITGA1, ITGAM USP2 3844/4885POLB 1327/4885MAPT 3320/4885
US-10716849-B2 Methods of administering novel integrin activator vaccine compositions ITGAM, ITGA2B, ITGA2 USP2 3347/4885POLB 2040/4885MAPT 4416/4885
US-20190351052-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS ITGAM, ITGA2B, ITGA1 USP2 3176/4885POLB 3717/4885MAPT 4082/4885
US-20190343952-A1 METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS ITGAM, ITGA2B, ITGA2 USP2 3347/4885POLB 2040/4885MAPT 4416/4885
US-20210145796-A1 METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY ITGB7, ITGA1, ITGAL USP2 4497/4885POLB 3578/4885MAPT 4582/4885
US-10709780-B2 Integrin activator vaccine compositions ITGAM, ITGA2B, ITGA1 USP2 3602/4885POLB 3356/4885MAPT 3888/4885
US-20210023207-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS ITGA2B, ITGAM, ITGAV USP2 3415/4885POLB 3658/4885MAPT 3756/4885
US-20240189360-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS CXCL12, ITGB3, ITGB7 USP2 3581/4885POLB 1947/4885MAPT 4072/4885
US-20160339098-A1 Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants CD4, CD274, ICOS USP2 4601/4885POLB 2358/4885MAPT 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.